Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-180291 SCHEMBL29502980 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| Ifetroban SCHEMBL28135 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| Ifetroban SCHEMBL30218601 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL28137 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL28136 | 1.00 | TBXA2R (1.00) | TBXA2R | |
| SCHEMBL8918573 | 0.99 | TBXA2R (1.00) | TBXA2R | |
| SCHEMBL8918962 | 0.99 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL16212977 | 0.99 | TBXA2R (0.98) | TBXA2R | |
| Bms-180291 SCHEMBL362595 | 0.99 | TBXA2R (0.98) | TBXA2R | |
| Ifetroban SCHEMBL16212975 | 0.99 | TBXA2R (0.98) | TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170319554-A1 | Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists | CUMBERLAND EMERGING TECHNOLOGIES, INC. | 2017-11-09 | — | — | US | claimed |
| US-20230381147-A1 | Ifetroban Treatment for Systemic Sclerosis | VANDERBILT UNIVERSITY | 2023-11-30 | — | — | US | disclosed |
| EP-3454850-B1 | COMPOSITIONS AND METHODS OF TREATING MUSCULAR DYSTROPHY WITH THROMBOXANE-A2 RECEPTOR ANTAGONISTS | CUMBERLAND PHARMACEUTICALS INC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20210137895-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | VANDERBILT UNIVERSITY | 2021-05-13 | — | — | US | disclosed |
| EP-3804717-A1 | COMPOSITIONS AND METHODS OF TREATING SYSTEMIC SCLEROSIS OR PULMONARY ARTERIAL HYPERTENSION | Cumberland Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200253935-A1 | Ifetroban Treatment for Systemic Sclerosis | NIH-DEITR | 2020-08-13 | — | — | US | disclosed |
| US-20200155512-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | VANDERBILT UNIVERSITY | 2020-05-21 | — | — | US | disclosed |
| US-10583126-B2 | Compositions and methods of treating cardiac fibrosis with ifetroban | CUMBERLAND PHARMACEUTICALS INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190247364-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | CUMBERLAND PHARMACEUTICALS INC. | 2019-08-15 | — | — | US | disclosed |
| US-10016399-B2 | Compositions and methods of treating cardiac fibrosis with ifetroban | CUMBERLAND PHARMACEUTICALS INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9994901-B2 | Pro-inflammatory mediators in diagnosis and treatment of chronic obstructive pulmonary disease | NATIONAL JEWISH HEALTH, A NON-PROFIT ORGANIZATION (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180050020-A1 | IFETROBAN TREATMENT OF PORTAL HYPERTENSION | CUMBERLAND PHARMACEUTICALS, INC. (US) | 2018-02-22 | — | — | US | disclosed |
| US-9820951-B2 | Pulmonary disease treatment and diagnosis based on Arhgef1 | NATIONAL JEWISH HEALTH, A NON-PROFIT ORGANIZATION (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170319554-A1 | Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists | CUMBERLAND EMERGING TECHNOLOGIES, INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170312255-A1 | IFETROBAN TREATMENT FOR SYSTEMIC SCLEROSIS | CUMBERLAND PHARMACEUTICALS, INC. (US) | 2017-11-02 | — | — | US | disclosed |
| US-20150051259-A1 | PRO-INFLAMMATORY MEDIATORS IN DIAGNOSIS AND TREATMENT OF PULMONARY DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2015-02-19 | — | — | US | disclosed |
| US-20130289121-A1 | PULMONARY DISEASE TREATMENT AND DIAGNOSIS BASED ON ARHGEF1 | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-10-31 | — | — | US | disclosed |
| US-5260449-A | Method for preparing 7-oxabicycloheptyl substituted bromooxazole amide prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds | E. R. SQUIBB & SONS, INC. (US) | 1993-11-09 | — | — | US | disclosed |